A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
UVA Human Immune Therapy Center
Oncovir, Inc.
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia
ClinicalTrials.gov Identifier:
NCT01585350
First received: April 24, 2012
Last updated: July 30, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)